Navigation Links
Xenon Announces Appointment of EVP, Research & Development
Date:5/17/2010

VANCOUVER, May 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce today that it has appointed Tarek S. Mansour as Executive Vice President, Research and Development.

"We are delighted to welcome Tarek to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "Tarek is a world-class R&D executive whose experience in discovering products, a number of which are now on the market, will further enhance Xenon's capabilities.  Tarek has had the unique experience of holding senior leadership positions within both biotech and more traditional pharmaceutical companies.  His successful careers at Biochem Pharma and Wyeth Pharmaceuticals (now Pfizer) have armed Tarek with best-in-class drug discovery and development practice and we are confident that Tarek will make a major contribution to Xenon's future innovative R&D efforts."

Dr. Mansour has spent nearly 25 years in the life sciences industry with positions at Biochem Pharma, and Wyeth Pharmaceuticals (now Pfizer). His most recent position at Wyeth Research was as VP, Chemical Sciences Head over multiple research sites. Dr. Mansour received his PhD in Chemistry from the University of Missouri - Columbia.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Biologic Products Announces First Quarter 2010 Results
2. Dehaier Medical Systems Announces First Quarter Net Income Up 54%
3. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
4. Still River Systems Announces Production Milestone for the Worlds Smallest High-Energy Proton Therapy Accelerator
5. joimax(R) Holds the First International TESSYS(R) User Meeting in Veenhuizen, The Netherlands, and Announces the Launch of Various New Products for Endoscopic Spinal Surgery
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
8. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
9. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
10. Cogdell Spencer Announces Commencement of Common Stock Offering
11. Mylan Announces Upsizing and Pricing of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for ... by age and sex in these markets. GD epidemiology report is written ... high quality, transparent and market-driven, providing expert analysis of disease trends in ... , Italy , Spain , ...
(Date:2/4/2016)... 4, 2016  The Senior Care Pharmacy Coalition ... Committee Chairman Jason Chaffetz (R-UT) and ... hearing , "Developments in the Prescription Drug ... growing questions about abusive pharmacy benefit manager (PBM) ... and Ranking Member Elijah Cummings (D-MD) are diligent, ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
Breaking Medicine Technology:
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Calls Blacklist ... a completely new user interface design and the developer has fixed known bugs within ... they want to on their phone while not consuming any of their device’s battery ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... that Medicare San Luis Obispo users can expect to see in 2016. To view ... two most significant changes will directly impact many San Luis Obispo seniors who rely ...
(Date:2/4/2016)... ... February 04, 2016 , ... According to a recent ... see their dentist once every six months for a cleaning and checkup, depending on ... Dr. Farzad Feiz, head dentist at Calabasas Dental Group and California Dental Care, notes ...
Breaking Medicine News(10 mins):